In a significant development, the much-anticipated merger of AYM Syntex and Mandawewala Enterprises has been given the green light by unsecured creditors. This approval, obtained during a virtual meeting held on May 25, 2026, is a step forward in consolidating the two companies' operations.

AYM Syntex experiences a remarkable 510% quarter-on-quarter jump in Q4 net profit to ₹9 Crore, thanks to operational improvements and increased demand. This growth has led to a revenue increase of 13%, reaching ₹365.77 Crore. Notably, the stock has climbed 61% from its 52-week low, demonstrating optimistic investor sentiment.

AYM Syntex shows a significant boost in Q4 EBITDA, climbing up to ₹333M from ₹267M year-over-year, indicating improved profitability. The company's earnings margin also expanded notably, rising to 9.1% from 7.4%. This suggests a healthier financial performance for AYM Syntex in the recent quarter.

Aym Syntex is set to announce their financial results for the fiscal year ended March 31, 2026 on May 19, 2026. The review includes both standalone and consolidated audited financial statements, along with the consideration of the statutory auditor's report.

Pharmaceutical company AYM Syntex incurs a Rs. 48.07 lakh GST penalty and faces a Rs. 10.27 lakh Input Tax Credit recovery demand for the fiscal year 2020-21. The company plans to appeal against this order.

AYM Syntex has scheduled a virtual meeting on May 25, 2026, for its equity shareholders and creditors to vote on the proposed merger with Mandawewala Enterprises. Electronic voting for this scheme begins on May 20 and ends on May 24, as per regulatory requirements.